Continuously growing interest for AcouSort’s research systems

19 September 2023 - 09:57

Over the past year, AcouSort has seen an increasing interest for the Company’s benchtop research systems. Most recently, AcouSort delivered and installed an AcouWash system at the Faculty of Medicine at the University of Porto, Portugal. This placement is the fifth AcouWash system delivered this year.

The AcouWash system delivered to the University of Porto will be used in a research project lead by Dr Raphaël Candas. The project aims to develop new methods to isolate, detect and characterize cancer cells in urine samples, which in turn may be an important step towards developing novel diagnostic tools. The AcouWash will contribute to the project by enabling a centrifuge-free separation and up-concentration of the cells.


“The possibility to collaborate with research groups provides AcouSort with great opportunities to broaden the scope of our technology and is thereby an important part of AcouSort’s continued development. By providing our customers within academia and industry benchtop research systems we are able to establish fruitful collaborations to explore new possibilities,” says Agnes Michanek, AcouSort’s Commercial Director.

For further information on AcouSort, please contact:

Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: [email protected]

About AcouSort

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company’s Certified Adviser is Erik Penser Bank.

Provided by: Cision
Nasdaq First North GM Stockholm (Sweden)
AcouSort AB
AcouSort is a is a biotech company which provides solutions for automated sample preparations involving biological cells or other organelles. Its technology is based on using ultrasound to isolate, separate or trap microscopic particles such as blood cells, bacteria or extracellular vesicles in microfluidic channels....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More